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Hematopoietic stem cell transplantation (HSCT) can
associated with T cell immunodeﬁciency which can
contribute to a high incidence of infections in patients. In the
thymus, hematopoietic progenitor cells undergo rapid
proliferation and differentiation to become mature T cells.
Factors which can affect the function of the thymus include:
age, high dose chemotherapy and radiotherapy, GVHD,
relapse and the occurrence of some opportunistic infections.
T cell rearrangement continues even in the elderly, and
because the TRECs are non-replicating episomal DNA and
their number can be decreased only by cell death, dilution
through cell division or both, the measurement of the
number of TRECs can be ameasure of immunity. The purpose
of this study was to measure T cell reconstitution after
hematopoietic stem cell transplantation in adult patients
with hematological malignancies by measuring TREC at
various time points after transplant.
To measure thymic output after HSCT, TREC levels were
measured in sixteen patients ages 23-68 (median age 53).
Two patients had CLL, one had follicular lymphoma and the
rest had acute leukemia (ten AML and three ALL). Ten
patients received myeloablative transplants and six received
reduced intensity transplants. All patients achieved full
donor chimerism at the time of analysis and all survived
aminimum of 6months after transplant (all but one survived
at least 500 days post-transplant). For the myeloablative
transplants, patients received 12 Gy of TBI followed by
a donor lymphocyte infusion of 2 x 108 CD3 cells/kg followed
two days later by cyclophosphamide at 60mg/kg/day for two
days followed one day later by a CD34 selected stem cell
product. For the non-myeloablative transplants, patients
received ﬂudarabine 30mg/m2 for four doses and cytarabine
2gm/m2 for four doses followed by 2 Gy of TBI then as
described for the myeloablative transplants. All patients
received tacrolimus and mycophenolate mofetil for GVHD
prophylaxis. The CD34 dose ranged from 1.40 - 5.89 x 106
cells/kg (median dose 3.34 x 106 cells/kg).
Peripheral blood samples were puriﬁed using the AUTO-
MACS magnetic cell sorter (Miltenyi Biotec). To determine
the purity of the CD4+ and CD8+ cells, two color cell staining
using ﬂuorochrome-conjugated antibodies against CD3+,
CD4+, CD8+ and CD56+ and ﬂow cytometry was performed.
TRECs were quantiﬁed by real-time polymerase chain reac-
tion (PCR) analysis using the 5’ nuclease (Taqman) assay. A
standard curve was plotted using samples with known
amounts of TREC, and TREC values for each sample was
calculated by the ABI7700 software. Samples were run and
analyzed in triplicate.Our analysis of the data showed that in general there
were more TREC's per 50,000 CD8 cells then CD4 cells.
Recipients with donors that had higher TRECs had more
TRECs after transplant and that with one exception the
number of TRECs in the recipient did not exceed that of the
donor.195
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Background: Reconstitution of the immune system
following allogeneic stem-cell transplantation (allo-SCT) is
a complex process that requires successful engraftment of
the hematopoietic stem cell, as well as adequate thymic
function. Although GVHD control, improvements in antibi-
otic spectra, and circumspection in the use of immunosup-
pressants have helped, too many patients still die of
infections because of insufﬁcient immunologic recovery.
Sirolimus has been used alone and in combination with
calcineurin inhibitors for prevention of allograft rejection
after solid organ transplantation. In the ﬁeld of hematopoi-
etic stem cell transplantation, the combination of sirolimus
and tacrolimus has also resulted in a low incidence of acute
GVHD and reduced transplant-related toxicity.
Methods: We evaluated the immune recovery status of
24 patients who received the combination of sirolimus
and tacrolimus as a GvHD prophylaxis compared to a
historical control (n¼21) using tacrolimus and methotre-
xate (MTX). They were conditioned with myeloablative
regimens.
Results: The incidence of acute GVHD in patients with siro-
limus based regimenwas lower. And the incidence of CMV or
EBV reactivation in the same group was higher. The recovery
of CD4+ Tcells and natural killer (NK) cells seemed to bemore
delayed in recipients with sirolimus based regimen
compared to those in patients with tacrolimus and MTX at 1
month after transplantation (8.8  1.6 vs 14.9  5.8 for CD4+
T cells, 35.7  6.4 vs 53.4  19.6 for NK cells). However, there
was no signiﬁcant difference between in the recovery of
CD4+T cells and NK cells at 3 months after transplantation. In
the aspect of humoral immunity, there was a trend to be
lower in immunoglobulin-A and Ig-M levels during 1 month
and 3months after transplantation in patients with sirolimus
based regimen. This difference was overcome around
post-transplant 6 months. And regulatory T cells
(CD4+CD25+Foxp3+) seemed to be higher in patients with
sirolimus based regimen.
Conclusion: The sirolimus based regimen is associated
with well-controlled acute GVHD. Although the correlation
between the increased risk of infection and delayed
immune reconstitution was not conﬁrmed, the regimen
might be cause of increasing the risk of opportunistic
infection. Therefore we need an effort of early tapering of
immunosuppressants and a careful monitoring for oppor-
tunistic infections in patients received sirolimus based
regimen.
